Primary biliary cholangitis – targeted to the farnesoid X receptor
Congress reportsGastroent Hepatol 2020; 74(5): 453–456. doi:10.14735/amgh2020453
pdf Kateřina MichnováTelemedicine is more than a „doctor on the phone“
AktualitaGastroent Hepatol 2021; 75(3): 263–265. doi: 10.48095/ccgh2021263
pdf Kateřina MichnováNews from the EASL-ILC congress: advances in the knowledge and treatment of primary biliary cholangitis
Congress reportGastroent Hepatol 2021; 75(4): 351–354. doi:10.48095/ccgh2021351
pdf Kateřina MichnováJanus kinase inhibitor in modern treatment of ulcerative colitis
Congress reportsGastroent Hepatol 2021; 75(6): 567–570. doi: 10.48095/ccgh2021567
pdf Kateřina MichnováSmoking and oncology – offering smokers a scientifically based, less harmful alternative is ethical
Congress reportsGastroent Hepatol 2021; 75(6): 571–573. doi: 10.48095/ccgh2021571
pdf Kateřina MichnováTofacitinib in the treatment of ulcerative colitis – personal experience
Congress reportGastroent Hepatol 2022; 76(2): 161–163.
pdf Kateřina MichnováExternal meeting of the CGS ČLS JEP committee in České Budějovice
Congress reportGastroent Hepatol 2022; 76(2): 164–165.
pdf Kateřina MichnováSubcutaneous Infliximab – the beginning of the era of biobetters in the treatment of immune-mediated inflammatory diseases
AktualitaGastroent Hepatol 2022; 76(3): 268–271.
pdf Kateřina MichnováThat’s how time passed with PBC – it is necessary to move one step forward again
AktualitaGastroent Hepatol 2022; 76(4): 359–363.
pdf Kateřina MichnováSecondary failure of biological treatment – a major challenge for biobetters
AktualitaGastroent Hepatol 2022; 76(5): 458–462.
pdf Kateřina Michnová